Vijay Pande
Bio + Health

Vijay Pande



More About Vijay

Vijay Pande, PhD, is a General Partner and has been at Andreessen Horowitz since 2014.  He founded and leads a16z Bio + Health, which invests in life sciences and healthcare through four dedicated funds with more than $3 billion under management. Vijay leads the firm’s investments at the cross section of biology and computer science, including applications in computation, machine learning, and artificial intelligence in healthcare; digital therapeutics; diagnostics; and other novel transformative scientific advances applied to industry that take bio beyond healthcare. He is also an Adjunct Professor of Structural Biology at Stanford University. He currently sits on the boards of Apeel Sciences, BioAge, Devoted Health, Freenome, Genesis Therapeutics, Insitro, Inceptive Therapeutics, Nautilus Biotechnology, Nobell, Omada Health,, SciFi Foods, and Scribe Therapeutics.

Prior to joining Andreessen Horowitz, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University, where he led a team of researchers pioneering computational methods and their application to medicine and biology (resulting in over 300 publications and six patents). Vijay was also concurrently the director of the Biophysics program at Stanford, where he led a team of more than 50 faculty members and propelled the program to the top in the country. Vijay also co-founded Globavir Biosciences, and founded the Folding@Home Distributed Computing Project.

Vijay holds a BA in Physics from Princeton University and a PhD in Physics from MIT. He has been awarded the DeLano Prize in Computation, a Guinness World Record for Folding@Home, the American Chemical Society Thomas Kuhn Paradigm Shift Award, and was selected for MIT TR10. In his teens, Vijay was the first employee at video game startup Naughty Dog, maker of Crash Bandicoot and The Last of Us.

Latest Content

  • AI in Pharmaceutical R&D with Kim Branson
    Kim Branson, Vijay Pande, Kris Tatiossian, and Olivia Webb

    Kim Branson, PhD, SVP and Global Head of AI and Machine Learning for GSK, joins Vijay Pande, founding partner at a16z Bio + Health. Together, they talk about how AI has improved drug discovery and development, as Kim walks through all the ways AI can be deployed in the lab.

  • Can AI Advance Science? DeepMind’s VP of Science Weighs In
    Steph Smith, Vijay Pande, and Pushmeet Kohli

    In recent years, the AI landscape has seen huge advancements, from the release of Dall-E 2 in April 2022 to the emergence of AI music and video models in early 2024. While creative tools often steal the spotlight, AlphaF...

  • Longevity as a Health Asset with Tom Hale
    Tom Hale, Vijay Pande, Daisy Wolf, Kris Tatiossian, and Olivia Webb

    Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health.

  • The Power of Drug Discovery with Philip Tagari
    Vijay Pande, Philip Tagari, Kris Tatiossian, and Olivia Webb

    Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.

  • AI-Enabled Continuity of Care with Ed and Todd Park
    Vijay Pande, Ed Park, Todd Park, Steph Smith, Kris Tatiossian, and Olivia Webb

    Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park.

Load More

Select Investments

Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments. A list of investments made by funds managed by a16z is available here:

go to top